¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"glucose effect"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • photoconductive effect
    ±¤ÀüµµÈ¿°ú
  • photoelectric effect
    ±¤ÀüÈ¿°ú
  • photovoltaic effect
    ±¤±âÀü·ÂÈ¿°ú
  • piezoelectric effect
    ¾ÐÀüÈ¿°ú
  • placebo effect
    ¼ÓÀÓ¾àÈ¿°ú, Çö󼼺¸È¿°ú
  • plateau effect
    °í¿øÈ¿°ú
  • polar effect
    ±Ø¼ºÈ¿°ú
  • polarizing effect
    ºÐ±ØÈ¿°ú
  • pooling effect
    Àú·ùÈ¿°ú
  • priming effect
    ½Ãµ¿È¿°ú
  • prolonged effect
    Áö¼ÓÈ¿°ú
  • partial volume effect
    ºÎºÐ¿ëÀûÈ¿°ú
  • palliative effect
    ¿ÏÈ­È¿°ú, °æ°¨È¿°ú
  • rush effect
    ¼âµµÈ¿°ú
  • radiation effect
    ¹æ»ç¼±È¿°ú
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • magnetic field effect
    ÀÚ±âÀåÈ¿°ú
  • magnetization transfer effect
    ÀÚ±âÈ­Àü´ÞÈ¿°ú
  • masking effect
    ÀºÆóÈ¿°ú
  • mass effect
    µ¢ÀÌÈ¿°ú
  • mesomeric effect
    °ø¸íÈ¿°ú
  • nonstochastic effect
    ºñÈ®·ü·ÐÀûÈ¿°ú
  • nonthermal effect
    ºñ¿­È¿°ú
  • oblique angle effect
    »ç°¢È¿°ú
  • obliquity effect
    ±â¿ï±âÈ¿°ú
  • on-off effect
    °³½ÃÁ¾·áÈ¿°ú
  • osmolality effect
    ¸ô¶ö»ïÅõ¾ÐÈ¿°ú
  • overkill effect
    °úÀ×Ä¡»çÈ¿°ú
  • palliative effect
    °í½ÄÀûÈ¿°ú, °æ°¨È¿°ú
  • partial volume effect
    ºÎºÐ¿ëÀûÈ¿°ú
  • phase shift effect
    À§»óº¯À§È¿°ú
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • T2 shortening effect
    T2 ´ÜÃà È¿°ú
  • Tyndall effect
    ƾ´ÞÈ¿°ú
  • additive effect
    ºÎ°¡È¿°ú
  • additive effect
    »ó°¡È¿°ú (ßÓÊ¥üùÍý)
  • adverse effect
    ¿ªÈ¿°ú(æ½üùÍý).¾à¸®À¯ÇØÈ¿°ú.
  • adverse effect
    ¿ªÈ¿°ú, À¯ÇØÈ¿°ú
  • air barrier effect
    °ø±â¸·È¿°ú(ÍöѨدüùÍý).
  • air gap effect
    °ø±â °£°Ý È¿°ú
  • allogeneic effect
    µ¿Á¾ÀÌÇüÈ¿°ú
  • analgesic effect
    ÁøÅëÈ¿°ú.
  • antagonistic effect
    ±æÇ×È¿°ú
  • anticoagulant effect
    Ç×ÀÀ°íÈ¿°ú.
  • anticurare effect
    Ç×Å¥¶ó·¹ÀÛ¿ë.
  • antioxidant effect
    Ç×»êÈ­È¿°ú(¡­üùÍý).
  • antitoxemic effect
    Ç×µ¶Ç÷ÁõÈ¿°ú.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • air gap effect
    °ø±â °£°Ý È¿°ú
  • allogeneic effect
    µ¿Á¾ÀÌÇüÈ¿°ú
  • analgesic effect
    ÁøÅëÈ¿°ú.
  • antagonistic effect
    ±æÇ×È¿°ú
  • anticoagulant effect
    Ç×ÀÀ°íÈ¿°ú.
  • anticurare effect
    Ç×Å¥¶ó·¹ÀÛ¿ë.
  • antioxidant effect
    Ç×»êÈ­È¿°ú(¡­üùÍý).
  • antitoxemic effect
    Ç×µ¶Ç÷ÁõÈ¿°ú.
  • antitussive effect
    ÁøÇØÈ¿°ú(òåú¦üùÍý).
  • back-pressure effect
    ÈĹæ¾Ð·ÂÈ¿°ú ¡ìÆóÁ¤¸Æ¿ïÇ÷¡í.»ý¸®ÈĹæ¾Ð·ÂÀÛ¿ë(ý­Û°äâæ³íÂéÄ).
  • bacteriostatic effect
    Á¤±ÕÈ¿°ú(¡­üùÍý).
  • beam hardening (effect)
    ºö°æÈ­È¿°ú
  • beam softening (effect)
    ºö¿¬È­È¿°ú
  • binaural hearing (effect)
    ¾çÀÌû(È¿°ú)
  • binaural hearing (effect)
    ¾çÀÌû(È¿°ú).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • photoelectric effect
    ±¤ÀüÈ¿°ú(ÎÃï³üùÍý)
  • piezoelectric effect
    ¾ÐÀü±âÈ¿°ú(äâï³Ñ¨üùÍý)
  • pressor effect
    Ç÷¾Ð È¿°ú(úìäâüùÍý)
  • primary charge effect
    ÀÏÂ÷ ÀüÇÏÈ¿°ú(ìéó­ï³ùÃüùÍý)
  • primary isotope effect
    ÀÏÂ÷ µ¿À§¿ø¼Ò È¿°ú(ìéó­ÔÒêÈêªáÈüùÍý)
  • propinquit effect
    ±ÙÁ¢È¿°ú(ÐÎïÈüùÍý)
  • proximity effect
    ±ÙÁ¢È¿°ú(ÐÎïÈüùÍý)
  • Raman effect
    ¶ó¸¸ È¿°ú(üùÍý)
  • relaxation effect
    ÀÌ¿Ï È¿°ú(ì¬èÐüùÍý)
  • secondary charge effect
    ÀÌÂ÷ ÇÏÀüÈ¿°ú(ì£ó­ùÃï³üùÍý)
  • secondary isotope effect
    ÀÌÂ÷ µ¿À§¿ø¼ÒÈ¿°ú(ì£ó­ÔÒêÈêªáÈüùÍý)
  • sparing effect
    ¿¹ºñÈ¿°ú(çãÝáüùÍý)
  • spreading position effect
    ÆÛÁü À§Ä¡ È¿°ú(êÈöÇüùÍý)
  • Stark effect
    ½ºÅ¸Å© È¿°ú(üùÍý)
  • thyrotoxic effect
    °©»ó¼±Áßµ¶ È¿°ú (Ë£ßÒàÍñéÔ¸üùÍý)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
IGFET insulated gate field effect transistor
ITE insufficient therapeutic effect; in the ear [hearing aid]; in-training examination; intrapulmonary i...
JFET junction field effect transistor
LEL lower explosive limit; lowest effect level
MOSFET metal oxide semiconductor field effect transistor
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
PEV Position effect variegation
PAE Post Antibiotic Effect
PAFE Post-antifungal effect
PNEC Predicted No Effect Concentration
RERF Radiation Effect Research Foundation
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • ration effect
    ¹æ»ç¼± È¿°ú
  • resonance effect
    °ø¸í È¿°ú
  • reverse piezoelectric effect
    ¿ª¾ÐÀü È¿°ú
  • RF antennae effect
    °íÁÖÆÄ ¾ÈÅ׳ª È¿°ú
  • second influencing effect
    ÀÌÂ÷ È¿°ú
  • sedative effect
    ÁøÁ¤ È¿°ú
  • sensory effect
    °¨°¢ È¿°ú
  • shearing effect
    Àü´Ü È¿°ú
  • shimmering effect : ÈíÀÎ ½Ã ÄÝ·¹½ºÅ×·ÑÀÌ °áÁ¤ÀÌ Æ÷ÇԵǾî ÀÖ´Â ¿¯Àº ¹Ð¤ »öÀÇ ¾×ü°¡ ³ª¿À¸ç ÀÌ ÄÝ·¹½ºÅ×·Ñ °áÁ¤Àº À¯¸®°ü¿¡ ³»¿ë¹°ÀÎ ¾×ü¸¦ ³Ö¾î ±¤¼± ¾Æ·¡¿¡¼­ ºñÃ纸¸é Ư¡ÀûÀÎ ºûÀ» ³»´Â Çö»ó.

    shimming

    º¸Á¤
  • sialogogic effect
    Ÿ¾× ºÐºñ ÃËÁø È¿°ú
  • side effect
    ºÎÀÛ¿ë
    »ç¿ëµÈ ¾àǰÀ̳ª ¾àÁ¦°¡ ¸ñÀû ÀÌ¿ÜÀÇ ´Ù¸¥ °á°ú, Áï ¹Ý´ë ÀÛ¿ëÀ¸·Î ¾à¹°¿¡ ´ëÇÑ À¯ÇØ ÀÛ¿ë, ƯÈ÷ ±× Åõ¿©·Î È¿´ÉÀ» Ãß±¸ÇÏ´Â °Í°ú ´Ù¸¥ Á¶Á÷À̳ª ±â°ü °èÅë¿¡ ¹ÌÄ¡´Â ÇØ·Î¿î ¿µÇâ°ú °°Àº °Í.
  • siphonage effect
    ½ÎÀÌÆù È¿°ú
  • snow-storm effect
    ´«º¸¶ó È¿°ú
  • somogyi effect
    ¼Ò¸ð±â È¿°ú
    Á¦ 1Çü ´ç´¢º´ ȯÀÚ¿¡¼­ ¾ß°£¿¡ ÀúÇ÷´çÁõÀÌ ¹ß»ýÇÏ´Â °æ¿ì ±æÇ× Á¶Àý È£¸£¸óÀÇ ºÐºñ¸¦ ÀÚ±ØÇÏ¿©
  • spin phase effect
    ½ºÇÉ À§»ó È¿°ú
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
UDP-glucose LOS-beta-1,4-glucosyltransferase <enzyme> Required for biosynthesis of lipooligosaccharide inner core extension in neisseria meningitidis; genbank u58765
Registry number: EC 2.4.1.-
Synonym: lgtf gene product
(26 Jun 1999)
UDP-glucose-N-acetylglucosaminyl pyrophosphorylundecaprenol glucosyltransferase <enzyme> From bacillus coagulans; catalyses the conversion of glcnac-pp-undecaprenol into glc(beta1-4)glcnac-pp-undecaprenol in the presence of udp-glucose
Registry number: EC 2.4.1.-
Synonym: udpglucose-glcnac-pp-undecaprenol glucosyltransferase, uggppugtransferase
(26 Jun 1999)
UDP-glucose solasodine glucosyltransferase <enzyme> Involved in the glycosylation of solasodine; from leaves of eggplant, solanum melongena
Registry number: EC 2.4.1.-
Synonym: udpglc solasodine glctase
(26 Jun 1999)
UDP-glucose spirostanol glucosyltransferase <enzyme> Involved in the glycosylation of spirostanol; from leaves of eggplant, solanum melongena
Registry number: EC 2.4.1.-
Synonym: udpglc spirostanol glctase
(26 Jun 1999)
fasting blood glucose <endocrinology, investigation> A method for finding out how much glucose (sugar) is in the blood. The test can show if a person has diabetes.
A blood sample is taken in a lab or doctor's office. The test is usually done in the morning before the person has eaten. The normal, nondiabetic range for blood glucose is from 70 to 110 mg/dl, depending on the type of blood being tested. If the level is over 140 mg/dl, it usually means the person has diabetes (except for newborns and some pregnant women).
(09 Oct 1997)
fasting glucose <endocrinology, investigation> A measurement of the blood glucose in the morning prior to the ingestion of any food for the prior 12 hours.
(27 Sep 1997)
UPD-glucose-thiohydroximate glucosyltransferase <enzyme> From brassica; catalyses the glucosylation of phenylacetothiohydroximate in the presence of udp-glucose to form desulfobenzylglucosinolate
Registry number: EC 2.4.1.-
Synonym: udp-glc-th-glucosyltransferase
(26 Jun 1999)
uridine diphosphate glucose <chemical> A key intermediate in carbohydrate metabolism. Serves as a precursor of glycogen, can be metabolised into udpgalactose and udpglucuronic acid which can then be incorporated into polysaccharides as galactose and glucuronic acid. Also serves as a precursor of sucrose lipopolysaccharides, and glycosphingolipids.
Chemical name: Uridine 5'-(trihydrogen diphosphate), P'-alpha-D-glucopyranosyl ester
(12 Dec 1998)
uridine diphosphate glucose dehydrogenase <enzyme> An enzyme that catalyses the oxidation of udpglucose to udpglucuronate in the presence of NAD+.
Chemical name: UDPglucose:NAD+ 6-oxidoreductase
Registry number: EC 1.1.1.22
(12 Dec 1998)
utp-glucose-1-phosphate uridylyltransferase <enzyme> An enzyme that catalyses the formation of udpglucose from utp plus glucose 1-phosphate.
Chemical name: UTP:alpha-D-glucose-1-phosphate uridylyltransferase
Registry number: EC 2.7.7.9
(12 Dec 1998)
4-coumaroyl-D-glucose hydroxylase <enzyme> From sweet potato roots (ipomoea batatas); catalyses the conversion of p-coumaroyl-d-glucose to caffeoyl-d-glucose for chlorogenic acid biosynthesis in the presence of ascorbic acid; mw 33 kD; has weak polyphenol oxidase activity; also hydroxylates p-coumaric acid
Registry number: EC 1.14.17.-
Synonym: p-coumaroyl-d-glucose hydroxylase, cdg hydroxylase
(26 Jun 1999)
liquid glucose A pharmaceutic aid consisting of dextrose, dextrins, maltose, and water, obtained by the incomplete hydrolysis of starch.
(05 Mar 2000)
abscopal effect A reaction produced following irradiation but occurring outside the zone of actual radiation absorption.
(05 Mar 2000)
additive effect <biochemistry, chemistry> An additive effect is the overall biological effect two chemicals acting together and which is the simple sum of the effects of the chemicals acting independently.
Compare: antagonism.
(15 Jan 1998)
adverse effect This is an abnormal or harmful effect to an organism caused by exposure to a chemical. It is indicated by some result such as death, a change in food or water consumption, altered body and organ weights, altered enzyme levels, or visible illness. An effect may be classed as adverse if it causes functional or anatomical damage, causes irreversible change in the homeostasis of the organism, or increases the susceptibility of the organism to other chemical or biological stress. A non-adverse effect will usually be reversed when the organism is no longer being exposed to the chemical.
(09 Oct 1997)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
ÅëÇÕ°Ë»ö ¿Ï·á